[1]
Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22(1): 76-98.
[2]
Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther 2003; 98(3): 269-97.
[3]
Stern-Ginossar N, Weisburd B, Michalski A, et al. Decoding human cytomegalovirus. Science 2012; 338(6110): 1088-93.
[4]
Britt WJ, Boppana S. Human cytomegalovirus virion proteins. Hum Immunol 2004; 65(5): 395-402.
[5]
Herbein G, Kumar A. The oncogenic potential of human cytomegalovirus and breast cancer. Front Oncol 2014; 4: 230.
[6]
Ahmed A. Immunopathology of CMV co-infection. MOJ Immunol 2014; 1: 1-6.
[7]
Naing ZW, Scott GM, Shand A, et al. Congenital cytomegalovirus infection in pregnancy: a review of prevalence, clinical features, diagnosis and prevention. Aust N Z J Obstet Gynaecol 2016; 56(1): 9-18.
[8]
Cannon MJ, Hyde TB, Schmid DS. Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. Rev Med Virol 2011; 21(4): 240-55.
[9]
Luscalov S, Loga L, Dican L, Junie LM. Cytomegalovirus infection in immunosuppressed patients after kidney transplantation. Clujul Med 2016; 89(3): 343-6.
[10]
Feldman DM, Keller R, Borgida AF. Toxoplasmosis, parvovirus, and cytomegalovirus in pregnancy. Clin Lab Med 2016; 36(2): 407-19.
[11]
Bhat V, Joshi A, Sarode R, Chavan P. Cytomegalovirus infection in the bone marrow transplant patient. World J Transplant 2015; 5(4): 287-91.
[12]
Luganini A, Terlizzi ME, Gribaudo G. Bioactive molecules released from cells infected with the human cytomegalovirus. Front Microbiol 2016; 7: 715.
[13]
McIntosh M, Hauschild B, Miller V. Human cytomegalovirus and transplantation: drug development and regulatory issues. J Virus Erad 2016; 2(3): 143-8.
[14]
Weber B, Prosser F, Munkwitz A, Doerr HW. Serological diagnosis of cytomegalovirus infection: comparison of 8 enzyme immunoassays for the detection of HCMV-specific IgM antibody. Clin Diagn Virol 1994; 2(4-5): 245-59.
[15]
Weber B, Berger A, Rabenau H. Human cytomegalovirus infection: diagnostic potential of recombinant antigens for cytomegalovirus antibody detection. J Virol Methods 2001; 96(2): 157-70.
[16]
Busse C, Strubel A, Schnitzler P. Combination of native and recombinant cytomegalovirus antigens in a new ELISA for detection of CMV-specific antibodies. J Clin Virol 2008; 43(2): 137-41.
[17]
Houghton RL, Benson DR, Reynolds L, et al. Multiepitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in patients with treated or untreated Chagas’ disease. J Infect Dis 2000; 181(1): 325-30.
[18]
Anandarao R, Swaminathan S, Khanna N. The identification of immunodominant linear epitopes of dengue type 2 virus capsid and NS4a proteins using pin-bound peptides. Virus Res 2005; 112(1-2): 60-8.
[19]
Anandarao R, Swaminathan S, Fernando S, Jana AM, Khanna N. Recombinant multiepitope protein for early detection of dengue infections. Clin Vaccine Immunol 2006; 13(1): 59-67.
[20]
Dipti CA, Jain SK, Navin K. A novel recombinant multiepitope protein as a hepatitis C diagnostic intermediate of high sensitivity and specificity. Protein Expr Purif 2006; 47(1): 319-28.
[21]
Duthie MS, Hay MN, Morales CZ, et al. Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis. Clin Vaccine Immunol 2010; 17(2): 298-303.
[22]
Cheng Z, Zhao JW, Sun ZQ, et al. Evaluation of a novel fusion protein antigen for rapid serodiagnosis of tuberculosis. J Clin Lab Anal 2011; 25(5): 344-9.
[23]
Dai J, Jiang M, Wang Y, Qu L, Gong R, Si J. Evaluation of a recombinant multiepitope peptide for serodiagnosis of Toxoplasma gondii infection. Clin Vaccine Immunol 2012; 19(3): 338-42.
[24]
de Souza MQ, Galdino AS, dos Santos JC, et al. A recombinant multiepitope protein for hepatitis B diagnosis. BioMed Res Int 2013.2013148317
[25]
Faria AR, de Castro Veloso L, Coura-Vital W, et al. Novel recombinant multiepitope proteins for the diagnosis of asymptomatic Leishmania infantum-infected dogs. PLoS Negl Trop Dis 2015; 9(1)e3429
[26]
Galdino AS, Santos JC, Souza MQ, et al. A novel structurally stable multiepitope protein for detection of HCV. Hepat Res Treat 2016; 20166592143
[27]
Lee HB, Piao DC, Lee JY, et al. Artificially designed recombinant protein composed of multiple epitopes of foot-and-mouth disease virus as a vaccine candidate. Microb Cell Fact 2017; 16(1): 33.
[28]
Schreterova E, Bhide M, Potocnakova L, Borszekova Pulzova L. Design, construction and evaluation of multi-epitope antigens for diagnosis of Lyme disease. Ann Agric Environ Med 2017; 24(4): 696-701.
[29]
Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2015; 10(6): 845-58.
[30]
Böhm G, Muhr R, Jaenicke R. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng 1992; 5(3): 191-5.
[31]
Sundqvist VA, Xu W, Wahren B. Antibody responses to synthetic peptides from cytomegalovirus phosphoprotein 150. J Clin Microbiol 1992; 30(10): 2735-9.
[32]
Greijer AE, van de Crommert JMG, Stevens SJC, Middeldorp JM. Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays. J Clin Microbiol 1999; 37(1): 179-88.
[33]
Maine GT, Stricker R, Schuler M, et al. Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzer. J Clin Microbiol 2000; 38(4): 1476-81.
[34]
Landini MP, Lazzarotto T. Prenatal diagnosis of congenital cytomegalovirus infection: light and shade Herpes. J Virol 1990; 6: 645-9.
[35]
Landini MP, Lazzarotto T, Maine GT, Ripalti A, Flanders R. Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay. J Clin Microbiol 1995; 33(10): 2535-42.
[36]
Landini MP, Ripalti A, Sra K, Pouletty P. Human cytomegalovirus structural proteins: immune reaction against pp150 synthetic peptides. J Clin Microbiol 1991; 29(9): 1868-72.
[37]
Marin LJ, Santos de Carvalho Cardoso E, Bispo Sousa SM, et al. Prevalence and clinical aspects of CMV congenital Infection in a low-income population. Virol J 2016; 13: 148.
[38]
Marsico C, Kimberlin DW. Congenital Cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment. Ital J Pediatr 2017; 43(1): 38.
[39]
Lanzieri TM, Dollard SC, Bialek SR, Grosse SD. Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. Int J Infect Dis 2014; 22: 44-8.
[40]
Emery VC, Lazzarotto T. Cytomegalovirus in pregnancy and the neonate. F1000 Res 2017; 6: 138.
[41]
Lancini D, Faddy HM, Flower R, Hogan C. Cytomegalovirus disease in immunocompetent adults. Med J Aust 2014; 201(10): 578-80.
[42]
Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets 2011; 11(5): 466-74.
[43]
Eguchi H, Horita N, Ushio R, et al. Diagnostic test accuracy of antigenaemia assay for PCR-proven cytomegalovirus infection-systematic review and meta-analysis. Clin Microbiol Infect 2017; 23(12): 907-15.
[44]
Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med 2011; 364(22): 2111-8.
[45]
Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010; 303(14): 1375-82.
[46]
Lazzarotto T, Dalla Casa B, Campisi B, Landini MP. Enzyme-linked immunoadsorbent assay for the detection of cytomegalovirus-IgM: comparison between eight commercial kits, immunofluorescence, and immunoblotting. J Clin Lab Anal 1992; 6(4): 216-8.
[47]
Genser B, Truschnig-Wilders M, Stünzner D, Landini MP, Halwachs-Baumann G. Evaluation of five commercial enzyme immunoassays for the detection of human cytomegalovirus-specific IgM antibodies in the absence of a commercially available gold standard. Clin Chem Lab Med 2001; 39(1): 62-70.
[48]
Olsen. Compositions and methods for the treatment and diagnosis of cytomegalovirus infection. JP5544309B2, 2014.
[49]
Oldstone MBA, Rice G. Diagnostic system for the detection of cytomegalovirus. EP0179152B1 1992.
[50]
Horaud F, Michelson S, Barzu O, Boue A, Amadei C. Monoclonal antibodies to cytomegalovirus and methods for the diagnosis in vitro of infections by human cytomegaloviruses, using monoclonal antibodies which react with a cytomegalovirus-induced protein kinase. EP0165830B1 1993.
[51]
Oldstone MBA, Rice G. Diagnostic system for the detection of cytomegalovirus. US4818678A 1989.
[52]
Diamond DJ. Diagnostic reagents for human cytomegalovirus and methods of use. US6733973B2 2004.
[53]
Gregory TM. Use of peptides to improve specificity of an immunoassay for the detection of cytomegalovirus specific IgM antibody. US6177241B1 2001.
[54]
Landini MP, Ripalti A, Gregory TM, Flanders RT. Recombinant mono and poly antigens to detect cytomegalovirus- specific IgM in human sera by enzyme immunoassay. US6074817A 2000.
[55]
Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev 2008; 72(2): 249-65.
[56]
Berth M, Grangeot-Keros L, Heskia F, Dugua JM, Vauloup-Fellous C. Analytical issues possibly affecting the performance of commercial human cytomegalovirus IgG avidity assays. Eur J Clin Microbiol Infect Dis 2014; 33(9): 1579-84.
[57]
Johnson WC. Circular dichroism and its empirical application to biopolymers. Methods Biochem Anal 1985; 31: 161-3.
[58]
Corrêa DHA, Ramos CHI. The use of circular dichroism spectroscopy to study protein folding, form and function. Afr J Biochem Res 2009; 3: 164-73.
[59]
Adler AJ. Green eld NJ, Fasman GD. Circular dichroism and optical rotatory dispersion of proteins and poly- peptides. Methods Enzymol 1973; 27: 675-735.
[60]
Dill KA. Dominant forces in protein folding. Biochemistry 1990; 29(31): 7133-55.
[61]
Buonsenso D, Serranti D, Gargiullo L, Ceccarelli M, Ranno O, Valentini P. Congenital cytomegalovirus infection: current strategies and future perspectives. Eur Rev Med Pharmacol Sci 2012; 16(7): 919-35.
[62]
Chiaie LD, Neuberger P, Vochem M, Lihs A, Karck U, Enders M. No evidence of obstetrical adverse events after hyperimmune globulin application for primary cytomegalovirus infection in pregnancy: experience from a single centre. Arch Gynecol Obstet 2018; 297(6): 1389-95.
[63]
Minsart AF, Smiljkovic M, Renaud C, et al. Use of cytomegalovirus-specific hyperimmunoglobulins in pregnancy: a retrospective cohort. J Obstet Gynaecol Can 2018; 40(11): 1409-16.
[64]
Gabrielli L, Bonasoni MP, Foschini MP, et al. Histological analysis of term placentas from hyperimmune globulin-treated and untreated mothers with primary cytomegalovirus infection. Fetal Diagn Ther 2019; 45(2): 111-7.
[65]
Jackson JW, Hancock TJ, Dogra P, et al. Anticytomegalovirus peptides point to new insights for CMV entry mechanisms and the limitations of in vitro screenings. MSphere 2019; 4(1): e00586-18.
[66]
Gerna G, Lilleri D. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine. New Microbiol 2019; 42(1): 1-20.
[67]
Tanimura K, Yamada H. Maternal and neonatal screening methods for congenital cytomegalovirus infection. J Obstet Gynaecol Res 2019; 45(3): 514-21.
[68]
Adler SP. Screening for cytomegalovirus during pregnancy. Infect Dis Obstet Gynecol 2011; 2011: 1-9.
[69]
Saldan A, Forner G, Mengoli C, Gussetti N, Palù G, Abate D. Testing for cytomegalovirus in pregnancy. J Clin Microbiol 2017; 55(3): 693-702.
[70]
Ribeiro PAF, Dias DS, Nogueira LM, Torres FAG, Felipe MSS. Proteína multiepitopo recombinante, seu processo de obtenção e suas aplicações relacionadas ao citomegalovirus. BR1020150075430 2015.
37
2